Rules and laws of drug hepatotoxicity.
Kaplowitz
Neil
N
USC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA. kaplowit@hsc.usc.edu
D016907:Adverse Drug Reaction Reporting Systems; D000410:Alanine Transaminase / Q000097:blood; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000201:enzymology / Q000209:etiology*; D002839:Chromans / Q000009:adverse effects*; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D045162:Thiazolidinediones / Q000009:adverse effects*; D000077288:Troglitazone; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D002839:Chromans; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000410:Alanine Transaminase; D000077288:Troglitazone; D001663:Bilirubin